Correction: (Title Correction) Nuvectis Announces Marketing Approval of Ciprocopan (NXP100) in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors
Go back to Correction: (Title Correction) Nuvectis Announces Marketing Approval of Ciprocopan (NXP100) in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors| (NASDAQ: NVCT) | Delayed: 21.98 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $21.98 | 52 Week High | $ | |||
| Open | $21.98 | 52 Week Low | $ | |||
| Day High | $21.98 | P/E | N/A | |||
| Day Low | $21.98 | EPS | $ | |||
| Volume | 1 | |||||
